Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Actinobac Biomed, Inc.
675 US Highway 1
North Brunswick, NJ, 08902
USA

People

Founder & Chair of the Scientific Advisory Committee
President & CEO

Funding

TOTAL $600k
FUNDING TOTAL $600k
Venture Round, 3/2009
Foundation Venture Capital Group
$500k
Series B, 2/2013
Foundation Venture Capital Group
$100k

Tags

Actinobac Biomed

Actinobac Biomed focuses on the development of pharmaceutical technologies derived from agents that target Leukocyte Function Antigen-1 (LFA-1).

The company’s lead product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells. In addition to its use as an effective targeted therapy agent for the treatment of hematologic malignancies, abundant evidence in literature suggests that Leukotoxin, or a derived product, can effectively be used to treat infectious diseases such as HIV/AIDS and tuberculosis, as well as many autoimmune diseases including rheumatoid arthritis, multiple sclerosis, Crohn’s disease, type 1 diabetes, Lupus and psoriasis.

Therefore, the company will direct its efforts in three strategic areas. The first, and highest priority, is the development of Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies. The second will focus on the use of Leukotoxin and derived therapeutic peptides or mimetics for the treatment of significant diseases other than hematologic malignancies, including infections and autoimmune diseases. The third area represents an early-stage drug discovery program with Magellan BioScience that will maintain a healthy pipeline of novel therapeutic agents.

Recent Milestones

Videos

Screenshots

Actinobac Biomed screenshot
Above: Actinobac Biomed Screenshot -- #1
Uploaded: 6/23/09

Sources

  1. Actinobac Biomed Receives Venture Capital Commitment (venturedeal.com) [edit]
  2. Foundation Venture Capital Group Commits Second Round of Funding to Actinobac Biomed (prnewswire.com) [edit]
Edit This Page
Last Edited 11/11/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy